

Adam Torbicki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8844806/publications.pdf>

Version: 2024-02-01

172
papers

94,440
citations

9756

73
h-index

5101

166
g-index

185
all docs

185
docs citations

185
times ranked

58623
citing authors

#	ARTICLE	IF	CITATIONS
1	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2013, 34, 2159-2219.	1.0	5,681
2	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. <i>European Heart Journal</i> , 2016, 37, 67-119.	1.0	5,074
3	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012, 33, 2569-2619.	1.0	5,034
4	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2014, 35, 2541-2619.	1.0	4,141
5	2013 ESC guidelines on the management of stable coronary artery disease. <i>European Heart Journal</i> , 2013, 34, 2949-3003.	1.0	3,915
6	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2014, 35, 2733-2779.	1.0	3,469
7	Guidelines on the management of valvular heart disease (version 2012). <i>European Heart Journal</i> , 2012, 33, 2451-2496.	1.0	3,465
8	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. <i>European Heart Journal</i> , 2012, 33, 2719-2747.	1.0	3,144
9	Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). <i>European Heart Journal</i> , 2009, 30, 2493-2537.	1.0	3,108
10	Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2008, 29, 2276-2315.	1.0	2,645
11	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014, 35, 3033-3080.	1.0	2,591
12	Third universal definition of myocardial infarction. <i>European Heart Journal</i> , 2012, 33, 2551-2567.	1.0	2,447
13	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Heart Journal</i> , 2020, 41, 543-603.	1.0	2,426
14	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. <i>European Respiratory Journal</i> , 2015, 46, 903-975.	3.1	2,415
15	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. <i>Europace</i> , 2012, 14, 1385-1413.	0.7	2,319
16	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. <i>European Journal of Heart Failure</i> , 2012, 14, 803-869.	2.9	2,307
17	2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). <i>European Heart Journal</i> , 2018, 39, 763-816.	1.0	2,305
18	Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2005, 353, 2148-2157.	13.9	2,237

#	ARTICLE	IF	CITATIONS
19	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>European Heart Journal</i> , 2013, 34, 2281-2329.	1.0	2,176
20	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2014, 46, 517-592.	0.6	2,164
21	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. <i>European Heart Journal</i> , 2016, 37, 2768-2801.	1.0	1,996
22	2015 ESC Guidelines for the diagnosis and management of pericardial diseases. <i>European Heart Journal</i> , 2015, 36, 2921-2964.	1.0	1,768
23	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2013, 34, 3035-3087.	1.0	1,758
24	ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011, 32, 3147-3197.	1.0	1,694
25	American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2003, 42, 1687-1713.	1.2	1,444
26	ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011, 32, 2851-2906.	1.0	1,394
27	Guidelines on the management of valvular heart disease (version 2012). <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 42, S1-S44.	0.6	1,313
28	Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2014, 370, 1402-1411.	13.9	1,221
29	Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2013, 369, 809-818.	13.9	1,168
30	Diagnosis and Assessment of Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S55-S66.	1.2	984
31	ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. <i>Journal of the American College of Cardiology</i> , 2001, 38, 1231-1265.	1.2	944
32	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. <i>European Journal of Heart Failure</i> , 2017, 19, 9-42.	2.9	920
33	Chronic Thromboembolic Pulmonary Hypertension (CTEPH). <i>Circulation</i> , 2011, 124, 1973-1981.	1.6	860
34	Diagnosis and differential assessment of pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, S40-S47.	1.2	819
35	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Respiratory Journal</i> , 2019, 54, 1901647.	3.1	806
36	Right Heart Adaptation to Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D22-D33.	1.2	770

#	ARTICLE	IF	CITATIONS
37	Editor's Choice "2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Journal of Vascular and Endovascular Surgery, 2018, 55, 305-368.	0.8	734
38	Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. Journal of the American College of Cardiology, 2002, 39, 1496-1502.	1.2	584
39	Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension. Journal of the American College of Cardiology, 2008, 52, 2127-2134.	1.2	506
40	Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension. Circulation, 2016, 133, 859-871.	1.6	506
41	Right heart thrombi in pulmonary embolism. Journal of the American College of Cardiology, 2003, 41, 2245-2251.	1.2	445
42	Rate Control vs Rhythm Control in Patients With Nonvalvular Persistent Atrial Fibrillation. Chest, 2004, 126, 476-486.	0.4	438
43	Mutations of the TGF- β 2 type II receptorBMP2 in pulmonary arterial hypertension. Human Mutation, 2006, 27, 121-132.	1.1	368
44	Management of venous thrombo-embolism: an update. European Heart Journal, 2014, 35, 2855-2863.	1.0	355
45	Serum N-Terminal Brain Natriuretic Peptide as a Prognostic Parameter in Patients With Pulmonary Hypertension. Chest, 2006, 129, 1313-1321.	0.4	354
46	Diagnosis, Assessment, and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension. Journal of the American College of Cardiology, 2009, 54, S85-S96.	1.2	353
47	Effects of the oral endothelin-receptorantagonist bosentan on echocardiographicand doppler measures in patients with pulmonary arterial hypertension. Journal of the American College of Cardiology, 2003, 41, 1380-1386.	1.2	334
48	Diagnosis of pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801904.	3.1	333
49	The pathophysiology of chronic thromboembolic pulmonary hypertension. European Respiratory Review, 2017, 26, 160112.	3.0	307
50	Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension. Circulation, 2013, 127, 624-633.	1.6	291
51	ERS statement on chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2021, 57, 2002828.	3.1	287
52	Detectable Serum Cardiac Troponin T as a Marker of Poor Prognosis Among Patients With Chronic Precapillary Pulmonary Hypertension. Circulation, 2003, 108, 844-848.	1.6	282
53	Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. European Respiratory Journal, 2012, 40, 874-880.	3.1	267
54	Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. European Heart Journal, 2018, 39, 4208-4218.	1.0	267

#	ARTICLE	IF	CITATIONS
55	Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. <i>European Respiratory Journal</i> , 2012, 40, 881-885.	3.1	221
56	Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial Hypertension. <i>Circulation</i> , 2009, 119, 1747-1757.	1.6	205
57	Cardiac Troponin T Monitoring Identifies High-Risk Group of Normotensive Patients With Acute Pulmonary Embolism. <i>Chest</i> , 2003, 123, 1947-1952.	0.4	203
58	Outcome after Cardiopulmonary Resuscitation in Patients with Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 341-344.	2.5	152
59	End points and clinical trial designs in pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, S48-S55.	1.2	147
60	Disturbed right ventricular ejection pattern as a new Doppler echocardiographic sign of acute pulmonary embolism. <i>American Journal of Cardiology</i> , 2002, 90, 507-511.	0.7	145
61	Atrial Septostomy in Treatment of End-Stage Right Heart Failure in Patients With Pulmonary Hypertension. <i>Chest</i> , 2007, 131, 977-983.	0.4	144
62	Left Atrial Appendage Dysfunction: A Cause of Thrombosis? Evidence by Transesophageal Echocardiography-Doppler Studies. <i>Journal of the American Society of Echocardiography</i> , 1991, 4, 435-441.	1.2	125
63	Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1668-1678.	1.8	121
64	Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 239-248.	5.2	116
65	Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension. <i>Thrombosis and Haemostasis</i> , 2013, 110, 83-91.	1.8	96
66	Pulmonary Artery Dilatation Correlates With the Risk of Unexpected Death in Chronic Arterial or Thromboembolic Pulmonary Hypertension. <i>Chest</i> , 2012, 142, 1406-1416.	0.4	90
67	Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1345-1354.	2.5	82
68	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. <i>Journal of the American College of Cardiology</i> , 2018, 71, 752-763.	1.2	82
69	Outcome of patients with right heart thrombi: the Right Heart Thrombi European Registry. <i>European Respiratory Journal</i> , 2016, 47, 869-875.	3.1	77
70	Balloon pulmonary angioplasty for the treatment of residual or recurrent pulmonary hypertension after pulmonary endarterectomy. <i>International Journal of Cardiology</i> , 2019, 278, 232-237.	0.8	69
71	Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct current cardioversion. <i>Clinical Cardiology</i> , 1997, 20, 337-340.	0.7	66
72	Prognostic Significance of Right Heart Thrombi in Patients With Acute Symptomatic Pulmonary Embolism. <i>Chest</i> , 2017, 151, 409-416.	0.4	65

#	ARTICLE	IF	CITATIONS
73	SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. <i>European Heart Journal</i> , 2017, 38, 1147-1155.	1.0	65
74	Detection of patients at risk for recurrence of atrial fibrillation after successful electrical cardioversion by signal-averaged P-wave ECG. <i>International Journal of Cardiology</i> , 1997, 60, 181-185.	0.8	56
75	Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 791-799.	2.3	53
76	Effect of Macitentan on Hospitalizations. <i>JACC: Heart Failure</i> , 2015, 3, 1-8.	1.9	51
77	Changing the strategy of balloon pulmonary angioplasty resulted in a reduced complication rate in patients with chronic thromboembolic pulmonary hypertension. A single-centre European experience. <i>Kardiologia Polska</i> , 2017, 75, 645-654.	0.3	51
78	Cardiac magnetic resonance in pulmonary arterial hypertension: a step in the right direction. <i>European Heart Journal</i> , 2007, 28, 1187-1189.	1.0	48
79	Improvement in Quality of Life and Hemodynamics in Chronic Thromboembolic Pulmonary Hypertension Treated With Balloon Pulmonary Angioplasty. <i>Circulation Journal</i> , 2017, 81, 552-557.	0.7	48
80	Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2017, 151, 106-118.	0.4	46
81	Summary of recommendations for the haemodynamic and angiographic assessment of the pulmonary circulation. Joint statement of the Polish Cardiac Society's Working Group on Pulmonary Circulation and Association of Cardiovascular Interventions. <i>Kardiologia Polska</i> , 2015, 73, 63-68.	0.3	44
82	Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. <i>European Respiratory Journal</i> , 2015, 46, 1711-1720.	3.1	39
83	Characterization of Patients with Pulmonary Arterial Hypertension: Data from the Polish Registry of Pulmonary Hypertension (BNP-PL). <i>Journal of Clinical Medicine</i> , 2020, 9, 173.	1.0	38
84	In-hospital major bleeding predicts mortality in patients with pulmonary embolism: An analysis of ZATPOL Registry data. <i>International Journal of Cardiology</i> , 2013, 168, 3543-3549.	0.8	35
85	Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension. <i>Heart</i> , 2017, 103, 599-606.	1.2	34
86	Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. <i>PLoS ONE</i> , 2018, 13, e0193226.	1.1	33
87	Characteristics and prognosis of patients with decompensated right ventricular failure during the course of pulmonary hypertension. <i>Kardiologia Polska</i> , 2008, 66, 1033-9; discussion 1040-1.	0.3	33
88	Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension. <i>Pulmonary Pharmacology and Therapeutics</i> , 2012, 25, 33-39.	1.1	32
89	Augmented reality and three-dimensional printing in percutaneous interventions on pulmonary arteries. <i>Quantitative Imaging in Medicine and Surgery</i> , 2019, 9, 23-29.	1.1	32
90	Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1059-1067.	1.6	30

#	ARTICLE	IF	CITATIONS
91	Recurrent Hemoptysis. <i>Chest</i> , 2011, 139, 690-693.	0.4	29
92	Role of echo/doppler in the diagnosis of pulmonary embolism. <i>Clinical Cardiology</i> , 1992, 15, 805-810.	0.7	28
93	Myoglobin stratifies short-term risk in acute major pulmonary embolism. <i>Clinica Chimica Acta</i> , 2003, 338, 53-56.	0.5	28
94	Outcome of Medically Versus Surgically Treated Patients With Chronic Thromboembolic Pulmonary Hypertension. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 92-99.	0.7	25
95	Treatment of chronic thromboembolic pulmonary hypertension in a multidisciplinary team. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661989152.	1.0	25
96	Proposed new pulmonary hypertension definition: is 4â€mm(Hg) worth re-writing medical textbooks?. <i>European Respiratory Journal</i> , 2019, 53, 1900197.	3.1	24
97	Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension: a multicentre registry. <i>EuroIntervention</i> , 2022, 17, 1104-1111.	1.4	23
98	The Role of Echocardiography in Suspected and Established PE. <i>Seminars in Vascular Medicine</i> , 2001, 01, 165-174.	2.1	21
99	Characteristics and outcomes of patients with chronic thromboembolic pulmonary hypertension in the era of modern therapeutic approaches: data from the Polish multicenter registry (BNP-PL). <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110029.	1.1	21
100	Hemodynamic Effects of Negative-Pressure Ventilation in Patients with COPD. <i>Chest</i> , 1990, 97, 850-856.	0.4	20
101	Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves functional class and pulmonary hemodynamics. <i>International Journal of Cardiology</i> , 2018, 269, 283-288.	0.8	20
102	Editorial Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. <i>Postepy W Kardiologii Interwencyjnej</i> , 2015, 1, 1-4.	0.1	19
103	Prostacyclin Analogues Inhibit Platelet Reactivity, Extracellular Vesicle Release and Thrombus Formation in Patients with Pulmonary Arterial Hypertension. <i>Journal of Clinical Medicine</i> , 2021, 10, 1024.	1.0	19
104	Noninvasive Diagnosis and Treatment of a Saddle Pulmonary Embolism. <i>Chest</i> , 1996, 109, 1124-1126.	0.4	18
105	Database of Pulmonary Hypertension in the Polish Population (BNPâ€PL): design of the registry. <i>Kardiologia Polska</i> , 2019, 77, 972-974.	0.3	18
106	Enfermedad tromboembÃ³lica pulmonar. Manejo clÃ¡nico de la enfermedad aguda y crÃ³nica. <i>Revista Espanola De Cardiologia</i> , 2010, 63, 832-849.	0.6	17
107	Fear of COVID-19, Anxiety and Depression in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension during the Pandemic. <i>Journal of Clinical Medicine</i> , 2021, 10, 4195.	1.0	17
108	An implantable pump Lenus proÃ in the treatment of pulmonary arterial hypertension with intravenous treprostinil. <i>BMC Pulmonary Medicine</i> , 2017, 17, 162.	0.8	16

#	ARTICLE	IF	CITATIONS
109	Balloon Pulmonary Angioplasty in Technically Operable and Technically Inoperable Chronic Thromboembolic Pulmonary Hypertension. <i>Journal of Clinical Medicine</i> , 2021, 10, 1038.	1.0	16
110	2015 ESC/ERS GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION. <i>Russian Journal of Cardiology</i> , 2016, , 5-64.	0.4	15
111	Long-term sinus rhythm maintenance after cardioversion of persistent atrial fibrillation: is the treatment's success predictable?. <i>Heart and Vessels</i> , 2006, 21, 375-381.	0.5	14
112	Actualizaci3n detallada de las gu3as de la ESC para el manejo de la fibrilaci3n auricular de 2012. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 54.e1-54.e24.	0.6	14
113	Acute and long term management of pulmonary embolism. <i>Heart</i> , 2010, 96, 1418-1424.	1.2	12
114	Changes in Estimated Glomerular Filtration after Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. <i>CardioRenal Medicine</i> , 2020, 10, 22-31.	0.7	12
115	Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension. <i>Kardiologia Polska</i> , 2013, 71, 1331-1331.	0.3	12
116	Management of pulmonary embolism: recent evidence and the new European guidelines. <i>European Respiratory Journal</i> , 2014, 44, 1385-1390.	3.1	11
117	Acute and chronic dissection of pulmonary artery: new challenges in pulmonary arterial hypertension?. <i>Pulmonary Circulation</i> , 2018, 8, 1-6.	0.8	11
118	Assessment of electrocardiographic markers of acute and long-term hemodynamic improvement in patients with pulmonary hypertension. <i>Annals of Noninvasive Electrocardiology</i> , 2020, 25, e12758.	0.5	11
119	Pulmonary Arterial Hypertension: Evaluation of the Newly Diagnosed Patient. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2005, 26, 372-378.	0.8	10
120	Cardio-oncological management of patients. <i>Seminars in Oncology</i> , 2019, 46, 408-413.	0.8	10
121	Balloon Pulmonary Angioplasty with Stent Implantation as a Treatment of Proximal Chronic Thromboembolic Pulmonary Hypertension. <i>Diagnostics</i> , 2020, 10, 363.	1.3	10
122	Expert opinion on the creating and operating of the regional Pulmonary Embolism Response Teams (PERT). Polish PERT Initiative. <i>Cardiology Journal</i> , 2020, 26, 623-632.	0.5	10
123	Left main artery compression by pulmonary artery aneurysm and ostial athero-stenosis of left anterior descending artery in a young female with pulmonary arterial hypertension. <i>European Heart Journal</i> , 2012, 33, 2621-2621.	1.0	9
124	Definition of pulmonary hypertension challenged?. <i>Nature Reviews Cardiology</i> , 2016, 13, 250-251.	6.1	9
125	Assessing the severity of acute pulmonary embolism: back to the future?. <i>European Heart Journal</i> , 2019, 40, 911-913.	1.0	9
126	Cardiac Troponins in Acute Pulmonary Embolism. <i>Chest</i> , 2002, 122, 2264.	0.4	8

#	ARTICLE	IF	CITATIONS
127	Role of cardiac biomarkers in assessment of RV function and prognosis in chronic pulmonary hypertension. Country Review Ukraine, 2007, 9, H41-H47.	0.8	8
128	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005095.	0.9	8
129	Soluble ST2 as a Biomarker for Early Complications in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty. Diagnostics, 2021, 11, 133.	1.3	8
130	Low DLCO in Idiopathic Pulmonary Arterial Hypertensionâ€”Clinical Correlates and Prognostic Significance. Pneumonologia I Alergologia Polska, 2016, 84, 87-94.	0.6	8
131	Severity of Arterial and Chronic Thromboembolic Pulmonary Hypertension is Associated with Impairment of Heart Rate Turbulence. , 2015, 20, 69-78.		7
132	COVID-19 and pulmonary embolism: an unwanted alliance. European Heart Journal, 2020, 41, 3069-3071.	1.0	7
133	Pregnancy as a predictor of deviations from the recommended diagnostic pathway in women with suspected pulmonary embolism: ZATPOL registry data. Archives of Medical Science, 2018, 14, 838-845.	0.4	6
134	The evolution of electrocardiographic signs of right ventricular overload after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. Polish Archives of Internal Medicine, 2019, 129, 451-459.	0.3	6
135	Circulating Blood-Based Biomarkers in Pulmonary Hypertension. Journal of Clinical Medicine, 2022, 11, 383.	1.0	6
136	Determinants of Survival After Emergency Intrapericardial Cisplatin Treatment in Cancer Patients with Recurrent Hemodynamic Instability After Pericardiocentesis. In Vivo, 2018, 32, 373-379.	0.6	5
137	Pulmonary Function Tests Leading to the Diagnosis of Vascular Malformations in School-Aged Children. Advances in Respiratory Medicine, 2017, 85, 253-257.	0.5	5
138	Prognostic staging of acute pulmonary embolism: are we closer to the holy grail?. European Respiratory Journal, 2014, 44, 565-567.	3.1	4
139	The multiple systemic artery to pulmonary artery fistulas resulting in severe irreversible pulmonary arterial hypertension in patient with previous history of pneumothorax. BMC Pulmonary Medicine, 2019, 19, 80.	0.8	4
140	Soluble ST2 protein as a new biomarker in patients with precapillary pulmonary hypertension. Archives of Medical Science, 2020, , .	0.4	4
141	Non-Tuberculous Mycobacterial Lung Disease (NTMLD) in Patients with Chronic Thromboembolic Pulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension. Pneumonologia I Alergologia Polska, 2014, 82, 495-502.	0.6	4
142	Centrilobular Nodules in High Resolution Computed Tomography of the Lung in IPAH Patientsâ€”Preliminary Data Concerning Clinico-Radiological Correlates. Pneumonologia I Alergologia Polska, 2016, 84, 265-270.	0.6	4
143	Neurohormonal modulation in right ventricular failure. Country Review Ukraine, 2007, 9, H35-H40.	0.8	3
144	Right Ventricle in Pulmonary Hypertension. Circulation: Cardiovascular Imaging, 2015, 8, .	1.3	3

#	ARTICLE	IF	CITATIONS
145	Prediction of Prognostic Hemodynamic Indices in Pulmonary Hypertension Using Non-Invasive Parameters. <i>Diagnostics</i> , 2020, 10, 644.	1.3	3
146	The "bouncing" catheter. <i>Cardiology Journal</i> , 2016, 23, 552-553.	0.5	3
147	Contemporary methods for the treatment of pulmonary embolism " is it prime-time for percutaneous interventions?. <i>Kardiologia Polska</i> , 2017, 75, 1161-1170.	0.3	3
148	"Syringe-in-the-Pocket"™ " A New Approach to the Outpatient Thromboembolic Prophylaxis of Recurrent Atrial Fibrillation. <i>Cardiology</i> , 2007, 107, 370-372.	0.6	2
149	In search of markers of treatment failure and poor prognosis in IPAH - the value of mosaic lung attenuation pattern on thin-section CT scans. <i>Multidisciplinary Respiratory Medicine</i> , 2010, 5, 409.	0.6	2
150	Assessment of Clinical Usefulness of Resting Electrocardiogram (PH-ECG Score) in Monitoring the Efficacy of Balloon Pulmonary Angioplasty (BPA) in Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH). <i>Journal of Clinical Medicine</i> , 2021, 10, 4548.	1.0	2
151	The importance of psychosocial factors in management of pulmonary arterial hypertension patients. <i>Kardiologia Polska</i> , 2018, 76, 529-535.	0.3	2
152	Precision medicine " the future of diagnostic approach to pulmonary hypertension?. <i>Anatolian Journal of Cardiology</i> , 2019, 22, 168-171.	0.5	2
153	Prostacyclin analogues decrease platelet aggregation but have no effect on thrombin generation, fibrin clot structure, and fibrinolysis in pulmonary arterial hypertension: PAPAYA coagulation. <i>Platelets</i> , 2022, 33, 1065-1074.	1.1	2
154	Macitentan for treatment of CTEPH: why MERIT merits attention. <i>Lancet Respiratory Medicine</i> , 2017, 5, 762-763.	5.2	1
155	Milestones in Understanding Pulmonary Circulation: From Antiquity to Heart-Lung Machine. <i>Diagnostics</i> , 2021, 11, 381.	1.3	1
156	Pulmonary Hypertension: Diagnosis and Management. <i>Diagnostics</i> , 2021, 11, 1066.	1.3	1
157	Functional class and type of pulmonary hypertension determinate severity. , 0, .		1
158	Pulmonary hypertension: diagnosis, differential diagnosis and pitfalls. , 2012, , 17-25.		1
159	Diagnosis and Assessment of Pulmonary Arterial Hypertension. , 0, , 7-46.		1
160	Predictive value of chest HRCT for survival in idiopathic pulmonary arterial hypertension. <i>Respiratory Research</i> , 2021, 22, 293.	1.4	1
161	An unusual case of CTEPH treated by BPA in a patient with a single lung after cancer surgery. <i>Pulmonary Circulation</i> , 0, , .	0.8	1
162	Characteristics and Outcomes of Patients Consulted by a Multidisciplinary Pulmonary Embolism Response Team: 5-Year Experience. <i>Journal of Clinical Medicine</i> , 2022, 11, 3812.	1.0	1

#	ARTICLE	IF	CITATIONS
163	Anomalous inferior vena cava mimicking aortic dissection on transesophageal echocardiography. <i>Clinical Cardiology</i> , 1993, 16, 571-572.	0.7	0
164	Noninvasive Tools to Monitor Pulmonary Hypertension. <i>Clinical Pulmonary Medicine</i> , 2007, 14, 232-239.	0.3	0
165	Foreword: right ventricular function and pulmonary hypertension. <i>Country Review Ukraine</i> , 2007, 9, H3-H4.	0.8	0
166	Polish Forum for Prevention: a response to the European Society of Cardiology "call for action"™ in Poland. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 250-250.	3.1	0
167	Acute coronary syndrome caused by compression of the left main coronary artery " the usefulness of computed tomography in diagnosis and interventional treatment planning. <i>Postepy W Kardiologii Interwencyjnej</i> , 2012, 1, 61-65.	0.1	0
168	Response to letter from dr Altmayer regarding publication "Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves functional class and pulmonary hemodynamics". <i>International Journal of Cardiology</i> , 2019, 276, 240-241.	0.8	0
169	Atrial Septostomy. , 2014, , 305-316.		0
170	Standardy hemodynamicznej i angiograficznej oceny kr...¼enia pÅ,ucnego Wsp³ne stanowisko Sekcji KrÅ...¼enia PÅ,ucnego i Asocjacji Interwencji Sercowo-Naczyniowych Polskiego Towarzystwa Kardiologicznego. <i>Kardiologia Polska</i> , 2014, 72, 45-64.	0.3	0
171	Vena cava superior stenting for rescue treatment of critical stenosis related to progressing cancer disease. <i>Kardiologia Polska</i> , 2016, 74, 601-601.	0.3	0
172	ERS statement on chronic thromboembolic pulmonary hypertension. <i>Pulmonologiya</i> , 2022, 32, 13-52.	0.2	0